Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05323656
Title A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic SCCHN
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genkyotex Suisse SA
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Pembrolizumab + Setanaxib

Age Groups: adult | senior
Covered Countries FRA | ESP


No variant requirements are available.